Mavenclad FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 6, 2019.
FDA Approved: Yes (First approved March 29, 2019)
Brand name: Mavenclad
Generic name: cladribine
Dosage form: Tablets
Company: EMD Serono, Inc.
Treatment for: Multiple Sclerosis
Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Development timeline for Mavenclad
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.